Davide Capodanno/X
Sep 4, 2025, 11:52
PARTHENOPE Trial: A New Benchmark in Risk Score Validation
Davide Capodanno, Professor of Cardiology at the University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on discrimination or area under the curve, but in reality, the true test of a score’s utility is whether randomization to a score-guided versus non–score-guided strategy makes a difference on clinical outcomes. Just think of how many scores we use every day that lack this kind of validation.”
Read more here.
Stay updated with Hemostasis Today.
-
Dec 8, 2025, 11:23Jorge Di Paola and Diane Krause Take Their Awards at ASH25
-
Dec 8, 2025, 11:08Andreas Tiede: This Will Change Hematology Forever
-
Dec 8, 2025, 09:39Asfand Yar Cheema Honored with Abstract Achievement Awards at ASH25
-
Dec 8, 2025, 09:27Ana Rita Rodrigues on the Impact of Post-Stroke Dysphagia
-
Dec 8, 2025, 09:19Sanam Loghavi and Shannon McWeeney at Joint Session on AI nad Hematology at ASH25
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 18:05Heghine Khachatryan Highlights a Patient-Friendly Breakthrough: Finger-Prick Micro-Sampling for Platelet Function
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI